Forbes August 7, 2024
Rita Numerof

On the heels of the FTC’s investigation into pharmacy benefit managers for what many regard as anti-competitive business practices, legal pressure is continuing to mount. At least six state Attorneys General, including California, Ohio and most recently Vermont, have initiated lawsuits against PBMs. Additionally, recent House oversight investigation findings bolster these claims, revealing that these drug middlemen–who claim to control costs–have instead “steered patients toward higher-priced medicines and affiliated pharmacies.”

As these inquiries, investigations and lawsuits keep PBM practices in the public eye, it’s important that lawmakers, employers and the general public understand not just what these practices are but how they relate to the larger healthcare market. PBMs are one piece of the jigsaw puzzle of healthcare, and they...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Congress / White House, Employer, Govt Agencies, Pharma, Pharma / Biotech
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal

Share This Article